Skip to main content

Table 3 Susceptibility of the regimen and RT-PR associated resistance mutations

From: HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

SampleaBackbone regimenRT mutationsPR mutationsSusceptible drugs (including RAL)b
2ETV + DRV/r3
3TDF + ZDV + LPV/r3
6TDF/FTCM184V, V179D2
7TDF + DRV/rK103N, Y318F3
8ETV + DRV/r + T20E44D, L210W, T215D, K103N, E138G, V179EV32I, M46I, I54L, V82T, I84V, L33F, T74P2
12TDF + ZDV + T20K103N, V108I, H221Y4
13TDF/FTC + DRV/rM41L, L74V, M184V, L210W, T215Y, K103S, G190A, F227LM46L, I54V, I84V, L24M, Q58E1
14TDF/FTCM41L, M184V, T215Y, K103N, K238T1
18ETV + DRV/rM184V, K103N, M230LL33F, M46I, I47V, I54M, V82M1
19TDF/FTCM41L, E44D, D67N, L74V, M184V, L210W, T215Y, K219E, L100I, K103NL90M2
21TPV/r + T20M41L, A62V, T69D, V75I, Y115F, F116Y, Q151M, M184V, L210W, T215Y, K219R, L100I, K103S, F22FLV32I, M46I, I54V, V82F, I84V, L90M, L33F, K43T, T74P2
23TDF + LPV/rM41L, T215YM46I, I54V, V82A, L24I1
24TDF/FTC + ATV/rD67N, T215A, K219Q3
25EFV + DRV/rM41L3
  1. RT reverse transcriptase, PR protease, ETV etravirine, DRV/r darunavir and ritonavir, TDF tenofovir, ZDV zidovudine, LPV/r lopinavir and ritonavir, FTC emtricitabine, T20 enfuvirtide, ABC abacavir, 3TC lamivudine, TPV/r tipranavir and ritonavir, EFV efavirenz
  2. aSamples from subjects with backbone resistance data available
  3. bNumber of drugs with a predicted resistance score < 15 (T20 was considered susceptible for all cases). n = 17